Novelix Pharmaceuticals Ltd

Novelix Pharma. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Novelix Pharmaceuticals Ltd

₹ 54.8 -2.14%
01 Jun - close price
trimurthidrugs.com BSE: 536565
About

Incorporated in 1994, Novelix Pharmaceuticals Ltd trades in Pharmaceuticals and related products , shares, and securities[1]

Key Points

Business Overview:[1][2][3]
NPL is a recent entrant in the life sciences research and pharmaceutical intermediates business. In FY24, the company altered its objectives to expand into the pharmaceutical bulk drug segment and healthcare research, analytics, and technology. Currently, it is engaged in pharmaceutical research and the production and trading of bulk drugs (Active Pharmaceutical Ingredients) as well as key starting materials and intermediates.

Website BSE
  • Market Cap ₹ 116 Cr.
  • Current Price ₹ 54.8
  • High / Low ₹ 70.2 / 27.9
  • Stock P/E 45.1
  • Book Value ₹ 22.0
  • Dividend Yield 0.00 %
  • ROCE 9.98 %
  • ROE 8.00 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.
  • Company's median sales growth is 42.1% of last 10 years
  • Company's working capital requirements have reduced from 222 days to 122 days

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding has decreased over last quarter: -2.55%
  • Company has a low return on equity of 5.12% over last 3 years.
  • Company has high debtors of 163 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Research, Analytics & Technology

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
0.87 1.95 0.93 0.50 0.84 0.60 3.96 5.30 20.86 22.35 36.36 48.40 25.19
1.07 2.14 1.04 0.61 0.69 1.04 3.74 5.17 20.63 22.17 35.66 47.09 23.91
Operating Profit -0.20 -0.19 -0.11 -0.11 0.15 -0.44 0.22 0.13 0.23 0.18 0.70 1.31 1.28
OPM % -22.99% -9.74% -11.83% -22.00% 17.86% -73.33% 5.56% 2.45% 1.10% 0.81% 1.93% 2.71% 5.08%
0.23 0.05 0.05 0.09 0.13 0.10 -0.08 0.00 0.00 0.00 0.03 0.00 0.00
Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Depreciation 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.02 0.01 0.01 0.03 0.05
Profit before tax 0.02 -0.15 -0.07 -0.03 0.27 -0.34 0.14 0.13 0.21 0.17 0.72 1.28 1.23
Tax % 0.00% 6.67% 0.00% 0.00% 0.00% 2.94% 0.00% -15.38% 14.29% 41.18% 26.39% 21.88% 26.02%
0.01 -0.17 -0.07 -0.03 0.28 -0.35 0.13 0.15 0.18 0.11 0.53 1.00 0.91
EPS in Rs 0.01 -0.21 -0.09 -0.04 0.35 -0.35 0.13 0.15 0.18 0.09 0.37 0.58 0.43
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1 1 4 3 4 2 1 1 2 4 31 132
1 1 3 3 3 1 4 3 2 4 31 129
Operating Profit 0 0 0 0 0 0 -3 -2 0 -0 0 3
OPM % 33% 43% 5% 15% 6% 12% -244% -151% 0% -6% 0% 3%
0 0 0 -0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0
Profit before tax 0 0 0 0 0 0 -3 -2 -0 0 0 3
Tax % 88% 31% 24% 34% -32% 20% 0% -1% 0% 50% 33% 25%
0 0 0 0 0 0 -3 -2 -0 0 0 3
EPS in Rs 0.02 0.12 0.19 0.22 0.31 0.11 -4.04 -1.93 -0.07 0.01 0.08 1.21
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 63%
5 Years: 152%
3 Years: 310%
TTM: 331%
Compounded Profit Growth
10 Years: 40%
5 Years: 23%
3 Years: 255%
TTM: 3100%
Stock Price CAGR
10 Years: 22%
5 Years: 47%
3 Years: 75%
1 Year: 96%
Return on Equity
10 Years: -1%
5 Years: 2%
3 Years: 5%
Last Year: 8%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 8 8 8 8 8 8 8 8 8 8 10 21
Reserves 3 3 3 4 4 4 1 -1 -1 -1 8 25
0 0 0 0 0 0 0 0 0 0 0 4
0 0 0 0 0 0 0 0 0 0 10 42
Total Liabilities 12 12 12 12 12 12 9 7 7 7 27 92
1 1 1 1 0 0 0 2 0 0 0 3
CWIP 0 0 0 0 0 0 0 0 0 0 0 0
Investments 1 3 2 3 3 4 4 1 3 3 0 0
9 8 9 9 9 8 5 5 4 4 27 89
Total Assets 12 12 12 12 12 12 9 7 7 7 27 92

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-0 2 -1 1 -0 1 1 1 -2 -0 -14
-0 -2 1 -1 0 -0 0 0 0 0 3
-0 0 0 0 0 0 0 0 0 0 11
Net Cash Flow -1 0 -0 -0 0 1 1 1 -2 -0 1
Free Cash Flow -1 2 -1 1 -0 1 0 -1 -2 -0 -14
CFO/OP -90% 472% -535% 225% -220% 672% -18% -34% 136% -9,771%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 30 4 40 130 216 19 25 32 36 1 216 163
Inventory Days 0 28 19 13 39 89 239 222 113 10 42
Days Payable 0 54 13 5 4 0 14 0 115 116
Cash Conversion Cycle 30 4 68 95 216 54 111 271 244 114 111 88
Working Capital Days 2,225 2,584 863 932 858 1,711 819 647 743 346 197 122
ROCE % 1% 1% 1% 3% 1% 1% -31% -19% -1% 0% 1% 10%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Number of Business Segments
Number

Log in to view insights

Please log in to see hidden values.

Login
Revenue contribution from Sale of Pharmaceuticals
INR in '000s
Number of Permanent Employees
Number
Trade Payables Turnover Ratio
Times
Trade Receivables Turnover Ratio
Times
Contribution of Interest Income to Turnover
Percentage
Contribution of Trading in Food Products to Turnover
Percentage
Number of R&D Labs Allotted
Number

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
66.92% 66.92% 66.92% 66.92% 66.54% 66.56% 66.56% 66.56% 52.75% 53.33% 51.97% 49.43%
33.08% 33.08% 33.08% 33.08% 33.46% 33.44% 33.45% 33.44% 47.25% 46.66% 48.01% 50.57%
No. of Shareholders 2,3912,3892,6212,6352,5692,5332,5022,4842,4082,6972,9942,975

Documents

Announcements

Annual reports